Northwest Bio jumps as Phase III trial keeps on rolling

In contrast to NewLink Genetics ($NLNK), Northwest Biotherapeutics' ($NWBO) interim analysis was a boon to the company's investors, as word that its Phase III trial of a personalized cancer vaccine was going according to plan sent its shares up as much as 10%. In a mid-trial review, Northwest's data monitoring board took a look at safety data from a study on the brain cancer-treating DCVax-L and recommended the trial continue. That cheered investors keeping tabs on the much-watched late-stage study, but the omission of efficacy data--for which a committee review is still pending, according to Northwest--has led some analysts to preach caution. More

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.